All In Biotech

Drug Trial Radar · NCT07902128

A Single-Center Phase 1 Study of ceAF for Knee Osteoarthritis (KOA)

A Research Collaboration Project to Evaluate the Efficacy and Safety of Animal Early Embryo Extract ceAF in the Treatment of Patients With Knee Osteoarthritis

Last checked: Nov 20, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

26

Planned (sponsor's estimate)

Start

Dec 10, 2025

Primary completion

Mar 2027

Study completion Nov 30, 2027

Sponsor

Sponsor type
Industry
First posted
Oct 28, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Approximately 25 participants aged 18-70 years, with knee pain rated 4-7 on a 10-point visual analogue scale (VAS) and a disease duration of 6 months to 10 years, will be enrolled. The study has two parts. In Part 1, participants receive a single intra-articular injection of 1.0 mL, 1.5 mL or 2.0 mL of study product (3-5 participants per dose level, given in ascending order). In Part 2, the dose with the most favourable balance of efficacy and safety in Part 1 is given weekly by intra-articular injection for 2-3 doses to an additional 6-10 participants. Participants are followed for 12 weeks after the last injection. Safety is assessed through adverse events (graded by CTCAE v5.0), vital signs, physical examination, electrocardiogram, clinical laboratory tests (haematology, urinalysis, liver and kidney biochemistry, coagulation) and pregnancy testing. Efficacy is assessed by change from baseline in knee X-ray, knee MRI, the Knee injury and Osteoarthritis Outcome Score (KOOS), the WOMAC index, pain VAS and pain-free walking distance at 4 and 12 weeks after the last dose. The study has no placebo or active comparator group. There is no plan to market the product on the basis of this study.

Conditions

  • Knee Arthritis, Osteoarthritis

Interventions

  • Animal early embryo extractBiological

    A cell-free biological preparation manufactured by Anhui Hygeiancells Co., Ltd. from early chick embryo amniotic fluid, containing composite growth-promoting factors and inflammatory factor inhibitors. Supplied as a sterile injection, 2 mL per bag, stored below -60 °C, shelf life 60 months. Administered by local intra-articular injection into the knee.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety observationTime frame: From informed consent signature through 12 weeks after the last injection
  2. Change from baseline in knee joint X-ray findingsTime frame: Baseline (screening) and 4 and 12 weeks after the last injection
  3. Change from baseline in Knee injury and Osteoarthritis Outcome Score (KOOS)Time frame: Baseline (screening) and 4 and 12 weeks after the last injection
  4. Change from baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)Time frame: Baseline (screening) and 4 and 12 weeks after the last injection
  5. Change from baseline in knee pain on a visual analogue scale (VAS)Time frame: Baseline (screening) and 4 and 12 weeks after the last injection

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Huangshan People's Hospital

    Huangshan City, Anhui, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.